Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27945934 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KDM4EKMT2AMAPTATM | |
| Pyrrolidine SCHEMBL15206059 | 0.98 | ALDH1A1 (0.33) | ALDH1A1KDM4EKMT2AMAPTATM | |
| Piperazine SCHEMBL17912476 | 0.89 | DGAT1 (0.33) | KDM4EKMT2AATMHPGDLMNA | |
| Cyclopentane SCHEMBL27520064 | 0.87 | DGAT1 (0.37) | KMT2AATMHPGDLMNAHSD17B10 | |
| SCHEMBL27766895 | 0.87 | DGAT1 (0.37) | KMT2AATMHPGDLMNAHSD17B10 | |
| Cyclohexane SCHEMBL9227267 | 0.87 | DGAT1 (0.37) | KMT2AATMHPGDLMNAHSD17B10 | |
| Cyclopropane SCHEMBL27493733 | 0.87 | DGAT1 (0.37) | KMT2AATMHPGDLMNAHSD17B10 | |
| Piperidine SCHEMBL28029475 | 0.81 | ALDH1A1 (0.39) | ALDH1A1HPGDDGAT1GAA | |
| SCHEMBL3094 | 0.79 | — | — | |
| SCHEMBL30234788 | 0.79 | DGAT1 (0.42) | ALDH1A1ATMLMNAHSD17B10DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483366-A | Benzazole compounds and preparation method thereof, pharmaceutical composition and purposes | INST MATERIA MEDICA CAMS | 2019-11-22 | — | — | CN | disclosed |
| CN-109790160-A | Pyrido 5-membered aromatic cyclics, preparation method and the usage | 上海海和药物研究开发有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-101595102-B | Diaryl ether urea compounds | PFIZER PROD INC | 2013-08-07 | — | — | CN | disclosed |
| CN-103025725-A | Heterocyclic compounds | ASTELLAS PHARMA INC | 2013-04-03 | — | — | CN | disclosed |
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| CN-101801933-A | quinolone derivative | ASTELLAS PHARMA INC | 2010-08-11 | — | — | CN | disclosed |
| CN-101595102-A | Diaryl ether urea compounds | PFIZER PROD INC (US) | 2009-12-02 | — | — | CN | disclosed |
| EP-2076508-A2 | BIARYL ETHER UREA COMPOUNDS | Pfizer Products Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080261941-A1 | Biaryl Ether Urea Compounds | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-10-23 | — | — | US | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| CN-1309638-A | N-substituted naphthamides as neurokinin receptor antagonists | ASTRAZENECA AB (SE) | 2001-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261941-A1 | Biaryl Ether Urea Compounds | FAAH, FAAH2, LIPC | ALDH1A1 360/4885KDM4E 1643/4885KMT2A 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.